Nature Reviews Cancer

Papers
(The H4-Index of Nature Reviews Cancer is 82. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)
ArticleCitations
The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy862
Targeting ferroptosis as a vulnerability in cancer724
Cancer metabolism: looking forward716
Therapeutic cancer vaccines671
RNA in cancer640
Systemic immunity in cancer621
A compendium of mutational cancer driver genes608
Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion578
Neutrophil diversity and plasticity in tumour progression and therapy552
Connecting copper and cancer: from transition metal signalling to metalloplasia542
Endoplasmic reticulum stress signals in the tumour and its microenvironment522
The role of ROS in tumour development and progression504
The rediscovery of platinum-based cancer therapy460
The matrix in cancer458
Recent advances and discoveries in the mechanisms and functions of CAR T cells451
The metabolism of cancer cells during metastasis447
p53: 800 million years of evolution and 40 years of discovery426
Metabolism of immune cells in cancer412
Key steps for effective breast cancer prevention390
Long noncoding RNAs in cancer metastasis347
Interleukins in cancer: from biology to therapy336
Advances in bladder cancer biology and therapy314
The cancer–natural killer cell immunity cycle313
The evolving translational potential of small extracellular vesicles in cancer304
The dormant cancer cell life cycle299
Non-genetic mechanisms of therapeutic resistance in cancer298
Linking EMT programmes to normal and neoplastic epithelial stem cells284
Exploiting senescence for the treatment of cancer283
Advancing targeted protein degradation for cancer therapy258
Cancer stem cell–immune cell crosstalk in tumour progression246
Natural killer cells in antitumour adoptive cell immunotherapy230
Mutations and mechanisms of WNT pathway tumour suppressors in cancer228
The immunological and metabolic landscape in primary and metastatic liver cancer227
Cancer progression and the invisible phase of metastatic colonization203
Autophagy in tumour immunity and therapy194
Targeting DNA damage response pathways in cancer184
The language of chromatin modification in human cancers183
Designing deep learning studies in cancer diagnostics182
Harnessing multimodal data integration to advance precision oncology177
Tumour fatty acid metabolism in the context of therapy resistance and obesity173
CRISPR in cancer biology and therapy173
A new dawn for eosinophils in the tumour microenvironment166
Targeting FAK in anticancer combination therapies161
The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs153
Genetic and non-genetic clonal diversity in cancer evolution151
Targeting the DNA damage response in immuno-oncology: developments and opportunities150
Targeting CDK4 and CDK6 in cancer149
Cancer nanomedicine146
Programmed death ligand 1 signals in cancer cells145
Antitumour immunity regulated by aberrant ERBB family signalling145
MYC protein interactors in gene transcription and cancer143
Sex disparities matter in cancer development and therapy138
Mutational signatures: emerging concepts, caveats and clinical applications135
Overcoming TGFβ-mediated immune evasion in cancer132
Towards targeting of shared mechanisms of cancer metastasis and therapy resistance131
Clonal expansion in non-cancer tissues130
Pancreatic cancer evolution and heterogeneity: integrating omics and clinical data129
Tumour-infiltrating B cells: immunological mechanisms, clinical impact and therapeutic opportunities127
Liquid–liquid phase separation drives cellular function and dysfunction in cancer124
The epigenomics of sarcoma121
2-Oxoglutarate-dependent dioxygenases in cancer121
Hyperinsulinaemia in cancer119
Prostate carcinogenesis: inflammatory storms116
Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer113
Stress and cancer: mechanisms, significance and future directions112
Aneuploidy as a promoter and suppressor of malignant growth108
Mitochondrial DNA variation and cancer105
Improving human cancer therapy through the evaluation of pet dogs105
The plasticity of mRNA translation during cancer progression and therapy resistance104
Mechanisms of immune activation and regulation: lessons from melanoma101
A timeline of tumour-associated macrophage biology101
Metabolic networks in mutant KRAS-driven tumours: tissue specificities and the microenvironment98
Advances in germline predisposition to acute leukaemias and myeloid neoplasms94
Tumour predisposition and cancer syndromes as models to study gene–environment interactions93
Polyamines in cancer: integrating organismal metabolism and antitumour immunity91
Artificial intelligence in cancer research, diagnosis and therapy90
Glial and myeloid heterogeneity in the brain tumour microenvironment89
RNA splicing dysregulation and the hallmarks of cancer89
Dysregulated haematopoietic stem cell behaviour in myeloid leukaemogenesis86
Synthetic biomarkers: a twenty-first century path to early cancer detection85
Cancer proteogenomics: current impact and future prospects84
Decoding leader cells in collective cancer invasion82
0.028049945831299